Joel M Montgomery
Overview
Explore the profile of Joel M Montgomery including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
198
Citations
5087
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Jain S, Shrivastava-Ranjan P, Flint M, Montgomery J, Spiropoulou C, Albarino C
Virology
. 2023 Sep;
588:109888.
PMID: 37774602
Arenaviruses are highly pathogenic viruses that pose a serious public health threat. Chapare virus (CHAV) and Machupo virus (MACV), two New World arenaviruses, cause hemorrhagic fevers with case fatality rates...
32.
McMillan R, Lo M, Zhang X, Beadle J, Valiaeva N, Garretson A, et al.
Antiviral Res
. 2023 Sep;
219:105718.
PMID: 37758067
Broad spectrum oral antivirals are urgently needed for the early treatment of many RNA viruses of clinical concern. We previously described the synthesis of 1-O-octadecyl-2-O-benzyl-glycero-3-phospho-RVn (V2043), an orally bioavailable lipid...
33.
Satter S, Aquib W, Sultana S, Sharif A, Nazneen A, Alam M, et al.
PLoS Negl Trop Dis
. 2023 Sep;
17(9):e0011617.
PMID: 37756301
Human Nipah virus (NiV) infection is an epidemic-prone disease and since the first recognized outbreak in Bangladesh in 2001, human infections have been detected almost every year. Due to its...
34.
Balinandi S, Whitmer S, Mulei S, Nassuna C, Pimundu G, Muyigi T, et al.
J Virol
. 2023 Sep;
97(10):e0059023.
PMID: 37750724
Ebola disease (EBOD) is a public health threat with a high case fatality rate. Most EBOD outbreaks have occurred in remote locations, but the 2013-2016 Western Africa outbreak demonstrated how...
35.
Kofman A, Haberling D, Mbuyi G, Martel L, Whitesell A, Van Herp M, et al.
Lancet Infect Dis
. 2023 Aug;
23(10):1111-1112.
PMID: 37604181
No abstract available.
36.
Sprecher A, Cross R, Marzi A, Martins K, Wolfe D, Montgomery J, et al.
J Infect Dis
. 2023 Aug;
228(Suppl 7):S474-S478.
PMID: 37596837
Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore,...
37.
Jain S, Lo M, Kainulainen M, Welch S, Spengler J, Satter S, et al.
Virology
. 2023 Aug;
587:109858.
PMID: 37544045
Nipah virus (NiV) is a highly pathogenic paramyxovirus with a high case fatality rate. Due to its high pathogenicity, pandemic potential, and lack of therapeutics or approved vaccines, its study...
38.
Welch S, Spengler J, Genzer S, Coleman-McCray J, Harmon J, Sorvillo T, et al.
Sci Adv
. 2023 Aug;
9(31):eadh4057.
PMID: 37540755
Nipah virus (NiV) causes a highly lethal disease in humans who present with acute respiratory or neurological signs. No vaccines against NiV have been approved to date. Here, we report...
39.
Nyakarahuka L, Kyondo J, Telford C, Whitesell A, Tumusiime A, Mulei S, et al.
Am J Trop Med Hyg
. 2023 Jul;
109(3):548-553.
PMID: 37524326
In 2016, an outbreak of Rift Valley fever was reported in the Kabale District in Uganda for the first time in 48 years. Three human cases were confirmed by polymerase...
40.
Loayza Mafayle R, Morales-Betoulle M, Whitmer S, Cossaboom C, Revollo J, Loayza N, et al.
Emerg Infect Dis
. 2023 Jul;
29(8):1705-1708.
PMID: 37486719
In May 2021, an agricultural worker originally from Trementinal, Argentina, sought treatment for febrile illness in Tarija, Bolivia, where he resided at the time of illness onset. The patient tested...